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doubling of risk of hematologic grade ≥3 toxicity based on 
previously published NTCP parameter estimates. NTCP 
modeling well predicted toxicity using IMRT in this sample. 
Predicted toxicity using CRT lay marginally outside 95% CI 
NTCP modeling in this sample. 
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Purpose/Objective: To facilitate a prompt recommendation 
of photon vs. proton therapy a decision support system (DSS) 
is essential. This paper presents the development and 
validation of an online, three-level (dose, normal tissue 
toxicity reduction and cost-effectiveness level) proton DSS, 
and its proposed application for patients with Head and Neck 
cancer. 
Materials and Methods: Meaningful benefits were defined for 
all three levels based on expert opinions and published 
papers. For the dose comparison layer, benefit was defined 
as a plan meeting clinical acceptable organs-at-risk 
thresholds: parotid gland <26Gy, pharyngeal constrictor 
muscle superior <50Gy, supraglottis area <50Gy. For the 
toxicity reduction layer, a clinical significant grade 2+ 
toxicity reduction was set at >10% based on a published 
toxicity prediction model for xerostomia and dysphagia at 6 
and 12 months after therapy. For the cost-effectiveness 
layer, the acceptable cost for a quality-adjusted life year 
(QALY) gained was set at 80.000€ and based on a published 
Markov model. The DSS was developed with a component 
oriented design and implementation to reuse independent in-
house resources in a systematic way and implements both the 
calculations and comparisons of photons vs. protons at the 
three levels (see figure). A Head and Neck cancer patient, 
planned with both IMRT and IMPT, was used to test the DSS. 
Results: A web-based DSS was successfully developed to 
deliver layered computation and comparison services. After 
providing clinical patient information and the photon and 
proton plans, the following comparison results were 
generated (see table): (1) On a dosimetric level, proton 
therapy generated a more desirable dose distributions; (2) On 
the toxicity estimation level, proton therapy appeared more 
capable of lowering the risk of complications for xerostomia 
or swallowing dysfunction; (3) On the cost-effectiveness 
level, proton therapy was more effective although photon 
therapy was more cost-effective. 
Conclusions: This DSS is able to quantitatively compare 
photon and proton treatment options and provide multi-level 
decision support. From the limited validation, proton therapy 
demonstrates its capacity to deliver a better dose 
distribution and lower toxicity to the normal tissue in 
comparison with photon therapy. However, given the current 
acceptable payment for a QALY gained, the lower costs of 
photon therapy appears to outweigh the benefits of proton 
therapy making photons more cost-effective for this specific 
case. 
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Purpose/Objective: The reduced concentration of oxygen in 
cells (hypoxia) results in a significantly lower cell death rate 
after exposure to ionizing radiation that can lead to 
treatment failure. This oxygen effect can be expressed by 
the oxygen enhancement ratio (OER) that was found 
experimentally to be strongly related to the quality of 
radiation and, in general, to the linear energy transfer (LET). 
Studies to quantify this effect in treatment simulations have 
been pursued [Wenzl T & Wilkens, JJ (2011) Phys Med Biol, 
56; Scifoni E, et al. (2013) Phys Med Biol, 58; Bassler N, et 
al. (2014) Acta Oncol 53]. However, systematic studies to 
evaluate the impact of hypoxia in treatments with beam of 
different ion species are still lacking. Furthermore, the 
radiobiological models used to quantify the OER in these 
studies are based on the dose averaged LET estimates and do 
not explicitly distinguish among varying ion species and 
fractionation schemes. In this work a new model to predict 
the OER taking into account the specificity of the different 
ions, tissues and fractionation schemes was implemented to 
quantify the clinical outcomes of treatments with beams of 
different ion species via an intercomparison of treatment 
plans for a set of clinical cases. 
Materials and Methods: A novel model, based on the 
microdosimetric effect model [Hawkins RB (2003) Rad Res, 
160], to predict the OER was implemented. The model was 
benchmarked with in-vitro data, V79 and HSG cells in aerobic 
and hypoxic conditions, irradiated with different ions 
[Furusawa Y, et al. (2000) Rad Res, 154]. The benchmarked 
model was then included in the simulation of treatment for a 
set of 12 clinical cases (head and neck and prostate cancer) 
using p, Li, He, C and O ion beams. The plans were evaluated 
using a treatment planning system (TPS) that is able to 
evaluate the LET spectra at a voxel level for primary and 
secondary particles. The expected treatment optimality as a 
function of oxygen partial pressure, HTV size, dose per 
fraction and primary ion type, was quantified in terms of 
Tumor Control Probability (TCP) and Normal Tissue 
Complication Probability (NTCP). 
Results: The modelled OERs were found to be dependent on 
both LET and ion charge, showing also a decreasing OER for 
increasing dose per fraction with a slope that depends on the 
LET. These behaviours were found to have a good agreement 
with the experimental OER assays. The treatment simulations 
shows a substantial OER dependence by dose per fraction and 
an increase in TCP by increasing the ion charge and dose per 
fraction (e.g. up to 40% variation from p to O). However, high 
NTCP in normal tissue for high-LET radiation was also 
observed. 
